Overview

Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

Status:
Completed

Trial end date:
2005-05-10

Target enrollment:

Participant gender:

Summary

This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and (ii) to obtain reference data for endpoints and dosage and administration of a next phase study.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Alosetron